
|Articles|June 9, 2008
Allergan buys Aczone Gel 5 percent from QLT USA
Irvine, Calif. - Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.
Advertisement
Irvine, Calif.
- Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.
Allergan will pay about $150 million for all assets related to Aczone, a topical treatment for acne vulgaris, which could reach revenues in excess of $75 million per year.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















